Business
Reviva Pharmaceuticals to Present at Upcoming Investor Conferences in May 2023
CUPERTINO, Calif., May 18, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage
About this update from Reviva Pharmaceuticals Holdings, Inc.
[{"type":"text","content":"CUPERTINO, Calif., May 18, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), respiratory and metabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will be presenting at two upcoming investor conferences to be held in May 2023. Details for the conferences can be found below: A.G.P.’S Virtual Healthcare Conference Date: Tuesday, May 23, 2023 Time: 12:00pm ET Format: Panel discussion (New approaches to depression & schizophrenia with Tonix & Reviva Pharmaceuticals – Improved options for these multi-billion dollar markets) and 1x1 investor meetings. Webcast Link: Click Here To register for A.G.P.’S Virtual Healthcare Conference please contact [email protected] Benchmark Virtual Healthcare House Call Conference Date: Tuesday, May 23, 2023 Format: 1x1 investor meetings To register for the Benchmark Virtual Healthcare House Call Conference please contact: Michael Fiorini – Director, Institutional Equity Sales at [email protected] About Reviva’s Lead Drug Candidate Brilaroxazine Brilaroxazine is a new chemical entity with potent affinity and selectivity against key serotonin and dopamine receptors implicated in schizophrenia and its comorbid symptoms. In a multinational, multicenter, double-blind Phase 2 study in 234 patients with acute schizophrenia or schizoaffective disorder, brilaroxazine met its primary endpoint, reducing Positive and Negative Syndrome Scale (PANSS) total score and demonstrating statistically significant improvement of overall drug treatment outcomes using Clinical Global Impression (CGI) scale and for secondary endpoints evaluating social functioning, and positive and negative symptoms, and directional improvements for depression and cognition. In this completed Phase 2 study, brilaroxazine met all safety endpoints with no weight gain, no increase in blood sugar and lipids, and no cardiac or endocrine adverse effects compared to placebo. Positive data from a clinical drug-drug interaction (DDI) study investigating the potential effect of CYP3A4 enzyme on brilaroxazine in healthy subjects supports no clinically significant interaction when combin...